NeilDavidPalmisianoMDMS
Oncology • Philadelphia, PAHematologic Oncology
Associate Professor of Medical Oncology
Dr. Palmisiano is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
925 Chestnut St
Ste 320A
Philadelphia, PA 19107Phone+1 215-955-8874Fax+1 215-955-2340
Education & Training
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 2011 - 2014- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2008 - 2011
Lewis Katz School of Medicine at Temple UniversityClass of 2008
Certifications & Licensure
NJ State Medical License 2018 - 2025
PA State Medical License 2008 - 2024
DE State Medical License 2018 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy Start of enrollment: 2013 Jul 08
- Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) Start of enrollment: 2016 Mar 01
- Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia Start of enrollment: 2018 Aug 13
- Join now to see all
Publications & Presentations
PubMed
- 13 citationsAcute Myeloid Leukemia: Update on Upfront Therapy in Elderly Patients.Gina Keiffer, Neil Palmisiano
Current Oncology Reports. 2019-06-27 - 38 citationsSafety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.Michael Heuser, Neil Palmisiano, Ioannis Mantzaris, Alice S. Mims, Courtney D. DiNardo
Leukemia. 2020-11-01 - 85 citationsIpilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multic...Catherine Diefenbach, Fangxin Hong, Richard F. Ambinder, Jonathon B. Cohen, Michael J. Robertson
The Lancet. Haematology. 2020-09-01
Abstracts/Posters
- Single Cell DNA Sequencing Identifies Combinatorial Mutation Patterns and Clonal Architecture in Myeloid MalignanciesNeil Palmisiano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid LeukemiaNeil Palmisiano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Authored Content
- IDH Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy at SOHO 2021September 2021
Press Mentions
Neil Palmisiano, MD, Appointed as Deputy Director of Phase 1 Therapeutics for Hematologic Malignancies at Rutgers Cancer Institute of New JerseyOctober 3rd, 2022- ASH 2023: Tailoring Treatment in AMLDecember 22nd, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
